The Stoxx Europe 600 hit a record high on Wednesday, in the latest sign of bullish sentiment among global investors. The broad-based European index rose 0.6 per cent to 529.14, led by stocks in the ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

The pan-European STOXX 600 was up 0.5%, as of 0822 GMT, and trading at its highest level since Sept. 27, 2024. Heavyweight ...

Europe’s Stoxx 600 index hit a record high for the first time since September, as investors grew optimistic that the harshest ...

The team categorized pediatric obesity treatment response, based on changes in body mass index standard deviation score, as ...

For several decades, the prevalence of steatotic liver disease (SLD) has been steadily increasing.1 Alterations in hepatic ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...